Stroke Treatment Delay Limits Outcome After Mechanical Thrombectomy: Stratification by Arrival Time and ASPECTS.


Journal

Journal of neuroimaging : official journal of the American Society of Neuroimaging
ISSN: 1552-6569
Titre abrégé: J Neuroimaging
Pays: United States
ID NLM: 9102705

Informations de publication

Date de publication:
09 2020
Historique:
received: 08 04 2020
revised: 07 05 2020
accepted: 08 05 2020
pubmed: 28 6 2020
medline: 7 4 2021
entrez: 28 6 2020
Statut: ppublish

Résumé

Mechanical thrombectomy (MT) has helped many patients achieve functional independence. The effect of time-to-treatment based in specific epochs and as related to Alberta Stroke Program Early CT Score (ASPECTS) has not been established. The goal of the study was to evaluate the association between last known normal (LKN)-to-puncture time and good functional outcome. We conducted a retrospective cohort study of prospectively collected acute ischemic stroke patients undergoing MT for large vessel occlusion. We used binary logistic regression models adjusted for age, Modified Treatment in Cerebral Ischemia score, initial National Institutes of Health Stroke Scale, and noncontrast CT ASPECTS to assess the association between LKN-to-puncture time and favorable outcome defined as Modified Rankin Score 0-2 on discharge. Among 421 patients, 328 were included in analysis. Increased LKN-to-puncture time was associated with decreased probability of good functional outcome (adjusted odds ratio [aOR] ratio per 15-minute delay = .98; 95% confidence interval [CI], .97-.99; P = .001). This was especially true when LKN-puncture time was 0-6 hours (aOR per 15-minute delay = .94; 95% CI, .89-.99; P = .05) or ASPECTS 8-10 (aOR = .98; 95% CI, .97-.99; P = .002) as opposed to when LKN-puncture time was 6-24 hours (aOR per 15-minute delay = .99; 95% CI, .97-1.00; P = .16) and ASPECTS <8 (aOR = .98; 95% CI, .93-1.03; P = .37). Decreased LKN-groin puncture time improves outcome particularly in those with good ASPECTS presenting within 6 hours. Strategies to decrease reperfusion times should be investigated, particularly in those in the early time window and with good ASPECTS.

Sections du résumé

BACKGROUND AND PURPOSE
Mechanical thrombectomy (MT) has helped many patients achieve functional independence. The effect of time-to-treatment based in specific epochs and as related to Alberta Stroke Program Early CT Score (ASPECTS) has not been established. The goal of the study was to evaluate the association between last known normal (LKN)-to-puncture time and good functional outcome.
METHODS
We conducted a retrospective cohort study of prospectively collected acute ischemic stroke patients undergoing MT for large vessel occlusion. We used binary logistic regression models adjusted for age, Modified Treatment in Cerebral Ischemia score, initial National Institutes of Health Stroke Scale, and noncontrast CT ASPECTS to assess the association between LKN-to-puncture time and favorable outcome defined as Modified Rankin Score 0-2 on discharge.
RESULTS
Among 421 patients, 328 were included in analysis. Increased LKN-to-puncture time was associated with decreased probability of good functional outcome (adjusted odds ratio [aOR] ratio per 15-minute delay = .98; 95% confidence interval [CI], .97-.99; P = .001). This was especially true when LKN-puncture time was 0-6 hours (aOR per 15-minute delay = .94; 95% CI, .89-.99; P = .05) or ASPECTS 8-10 (aOR = .98; 95% CI, .97-.99; P = .002) as opposed to when LKN-puncture time was 6-24 hours (aOR per 15-minute delay = .99; 95% CI, .97-1.00; P = .16) and ASPECTS <8 (aOR = .98; 95% CI, .93-1.03; P = .37).
CONCLUSION
Decreased LKN-groin puncture time improves outcome particularly in those with good ASPECTS presenting within 6 hours. Strategies to decrease reperfusion times should be investigated, particularly in those in the early time window and with good ASPECTS.

Identifiants

pubmed: 32592619
doi: 10.1111/jon.12729
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

625-630

Informations de copyright

© 2020 American Society of Neuroimaging.

Références

Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11-20.
Chalos V, LeCouffe NE, Uyttenboogaart M, et al. Endovascular treatment with or without prior intravenous alteplase for acute ischemic stroke. J Am Heart Assoc 2019;8:e011592.
Jahan R, Saver JL, Schwamm LH, et al. Association between time to treatment with endovascular reperfusion therapy and outcomes in patients with acute ischemic stroke treated in clinical practice. JAMA 2019;322:252-63.
Mulder M, Jansen IGH, Goldhoorn RB, et al. Time to endovascular treatment and outcome in acute ischemic stroke: MR Clean Registry results. Circulation 2018;138:232-40.
Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378:11-21.
He AH, Churilov L, Mitchell PJ, et al. Every 15-min delay in recanalization by intra-arterial therapy in acute ischemic stroke increases risk of poor outcome. Int J Stroke 2015;10:1062-7.
Wheeler HM, Mlynash M, Inoue M, et al. The growth rate of early DWI lesions is highly variable and associated with penumbral salvage and clinical outcomes following endovascular reperfusion. Int J Stroke 2015;10:723-9.
Saver JL, Goyal M, van der Lugt A, et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA 2016;316:1279-88.
Sheth SA, Jahan R, Gralla J, et al. Time to endovascular reperfusion and degree of disability in acute stroke. Ann Neurol 2015;78:584-93.
Chen H, Gong X, Xu D, et al. [Advanced treatment time improves outcomes of patients with ischemic stroke undergoing reperfusion therapy]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2019;48:247-53.
Demeestere J, Garcia-Esperon C, Garcia-Bermejo P, et al. Evaluation of hyperacute infarct volume using aspects and brain ct perfusion core volume. Neurology 2017;88:2248-53.
Rocha M, Desai SM, Jadhav AP, et al. Prevalence and temporal distribution of fast and slow progressors of infarct growth in large vessel occlusion stroke. Stroke 2019;50:2238-40.
Broocks G, Rajput F, Hanning U, et al. Highest lesion growth rates in patients with hyperacute stroke. Stroke 2019;50:189-92.
Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018;49:e46-e110.
Choi PMC, Tsoi AH, Pope AL, et al. Door-in-door-out time of 60 minutes for stroke with emergent large vessel occlusion at a primary stroke center. Stroke 2019;50:2829-34.
McTaggart RA, Moldovan K, Oliver LA, et al. Door-in-door-out time at primary stroke centers may predict outcome for emergent large vessel occlusion patients. Stroke 2018;49:2969-74.
Jayaraman MV, Hemendinger ML, Baird GL, et al. Field triage for endovascular stroke therapy: a population-based comparison. J Neurointerv Surgery 2019;12:233-9.
Ovbiagele B, Saver JL. Day-90 acute ischemic stroke outcomes can be derived from early functional activity level. Cerebrovasc Dis 2010;29:50-56.

Auteurs

Thomas Snyder (T)

Department of Neurology, New York Langone Medical Center, New York, NY.

Shashank Agarwal (S)

Department of Neurology, New York Langone Medical Center, New York, NY.

Jeffrey Huang (J)

Department of Radiology, New York Langone Medical Center, New York, NY.

Koto Ishida (K)

Department of Neurology, New York Langone Medical Center, New York, NY.

Brent Flusty (B)

Department of Neurology, New York Langone Medical Center, New York, NY.

Jennifer Frontera (J)

Department of Neurology, New York Langone Medical Center, New York, NY.

Aaron Lord (A)

Department of Neurology, New York Langone Medical Center, New York, NY.

Jose Torres (J)

Department of Neurology, New York Langone Medical Center, New York, NY.

Cen Zhang (C)

Department of Neurology, New York Langone Medical Center, New York, NY.

Sara Rostanski (S)

Department of Neurology, New York Langone Medical Center, New York, NY.

Albert Favate (A)

Department of Neurology, New York Langone Medical Center, New York, NY.

Kaitlyn Lillemoe (K)

Department of Neurology, New York Langone Medical Center, New York, NY.

Matthew Sanger (M)

Department of Neurology, New York Langone Medical Center, New York, NY.

Sun Kim (S)

Department of Neurology, New York Langone Medical Center, New York, NY.

Kelley Humbert (K)

Department of Neurology, New York Langone Medical Center, New York, NY.

Erica Scher (E)

Department of Neurology, New York Langone Medical Center, New York, NY.

Seena Dehkharghani (S)

Department of Radiology, New York Langone Medical Center, New York, NY.

Eytan Raz (E)

Department of Radiology, New York Langone Medical Center, New York, NY.

Maksim Shapiro (M)

Department of Radiology, New York Langone Medical Center, New York, NY.

Peter K Nelson (P)

Department of Radiology, New York Langone Medical Center, New York, NY.

David Gordon (D)

Department of Neurosurgery, New York Langone Medical Center, New York, NY.

Omar Tanweer (O)

Department of Neurosurgery, New York Langone Medical Center, New York, NY.

Erez Nossek (E)

Department of Neurosurgery, New York Langone Medical Center, New York, NY.

Jeffrey Farkas (J)

Department of Neurology, New York Langone Medical Center, New York, NY.
Department of Radiology, New York Langone Medical Center, New York, NY.

Jeremy Liff (J)

Department of Neurology, New York Langone Medical Center, New York, NY.

David Turkel-Parrella (D)

Department of Neurology, New York Langone Medical Center, New York, NY.

Ambooj Tiwari (A)

Department of Neurology, New York Langone Medical Center, New York, NY.

Howard Riina (H)

Department of Neurosurgery, New York Langone Medical Center, New York, NY.

Shadi Yaghi (S)

Department of Neurology, New York Langone Medical Center, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH